Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
There are questions about vuso-vec’s supporting and confirmatory trials.
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
